NASDAQ:ATXI
Avenue Therapeutics, Inc. Stock Company Profile
$6.20
+6.08 (+5,199.15%)
At Close: Apr 26, 2024
Information
1140 Avenue of the America, 9th Floor
New York NY 10036
781 652 4500
www.avenuetx.com
Industry: Biotechnology
Sector: Healthcare
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.